Would you offer PMRT to ER/PR+ patients with synchronous bone metastasis?

In what scenarios do the benefits of local control with PMRT outweigh the risks?

How would systemic therapy and/or the number of bone metastases impact your decision?

Answer from: Radiation Oncologist at Academic Institution

This is a more common scenario despite data suggesting a local survival benefit with the addition of local therapy to patients with metastatic breast cancer. With synchronous bone mets- we usually start with systemic therapy, ER+ would be endocrine therapy + CDK 4/6 inhibitor commonly. If stable/re...

Comments

Radiation Oncologist at Hollings Cancer Center, Medical University of South Carolina
Do you have a reference for the bone met dosing or...

Radiation Oncologist at Cleveland Clinic
This is based on NRG BR001: Chmura et al., PMID 33...

Answer from: Radiation Oncologist at Community Practice

We now have a prospective, randomized trial addressing this issue and it does NOT show an Overall Survival Benefit. Although it was associated with improved locoregional control, this had NO overall impact on quality of life either. Khan et al., PMID 34995128

Answer from: Radiation Oncologist at Community Practice

In general, once local treatment (surgery) route is taken in MDT then follow PMRT for anyone with high risk features (stage III disease) understating that we don’t know of its benefits in terms of survival. Clinical trials done had their own limitations and none added local treatment to metast...

Comments

Radiation Oncologist at Washington University School of Medicine
I agree with Dr. @Sushil Beriwal's opinion. I add ...

Please select the option that best describes you:

Would you offer PMRT to ER/PR+ patients with synchronous bone metastasis?

Related Questions